Literature DB >> 9740688

Steroid receptor expression in endometria from women treated with tamoxifen.

F Kommoss1, U Karck, H Prömpeler, J Pfisterer, C J Kirkpatrick.   

Abstract

Breast cancer patients receiving tamoxifen (Tam) are at an increased risk for developing endometrial carcinomas, possibly due to the partial estrogenic effect of Tam on endometrial cells. Progestational therapy has not routinely been included in Tam regimens. It was our aim to determine the presence of estrogen receptors (ERs) and progesterone receptors (PRs) in normal and abnormal endometria from postmenopausal women with breast cancer who were treated with Tam. Standard immunohistochemical staining of ERs and PRs was performed on paraffin sections from formalin-fixed uterine curettings or hysterectomy specimens from 40 patients who had received 20-40 mg of Tam daily for a minimum of 3 months. For comparison, normal endometria from 20 women who had not received Tam (11 premenopausal, 9 postmenopausal) were also studied for ER and PR expression. Staining was evaluated using semiquantitative immunoreactivity scores (IRS) ranging from 0 (negative) to 12 (strongly positive). In the group of patients receiving Tam, ERs and PRs were detected in the nuclei of glandular cells in 24/24 cases of endometrial atrophy (ER/PR-IRS, 2-12), in 8/8 endometrial polyps (ER-IRS, 6-12; PR-IRS, 4-12), in 4/4 adenomatous endometrial hyperplasias (ER-IRS, 3-8; PR-IRS, 1-12), and in 4/4 well-differentiated endometrioid adenocarcinomas (ER-IRS, 2-12; PR-IRS, 6-8). Of the 11 endometria from premenopausal patients who had not received Tam, 8 were ER+/PR+ (ER-IRS, 1-12; PR-IRS, 1-12), 1 was ER+/PR- (ER-IRS, 3; PR-IRS, 0), 1 was ER-/PR+ (ER-IRS, 0; PR-IRS, 2), and 1 was ER-/PR- (ER/PR-IRS, 0). Among 9 atrophic endometria from women not treated with Tam, 6 were ER+/PR+ (ER-IRS, 4-12; PR-IRS, 3-6), 1 was ER+/PR- (ER-IRS, 4; PR-IRS, 0), and 2 were ER-/PR- (ER/PR-IRS, 0). The consistent finding of ER and PR expression in endometria from postmenopausal women receiving Tam further supports the suspected estrogenic effect exerted by Tam on endometrial cells. Progestational therapy could be beneficial in the prevention of Tam-induced abnormal endometrial proliferations. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9740688     DOI: 10.1006/gyno.1998.5087

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  [Changes in the endometrium after tamoxifen therapy].

Authors:  D Schmidt
Journal:  Pathologe       Date:  2006-02       Impact factor: 1.011

2.  The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium.

Authors:  M J E Mourits; K A Ten Hoor; A G J van der Zee; P H B Willemse; E G E de Vries; H Hollema
Journal:  J Clin Pathol       Date:  2002-07       Impact factor: 3.411

Review 3.  Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer.

Authors:  J Julie Kim; Takeshi Kurita; Serdar E Bulun
Journal:  Endocr Rev       Date:  2013-01-09       Impact factor: 19.871

4.  Tumorigenic effects of tamoxifen on the female genital tract.

Authors:  Kaei Nasu; Noriyuki Takai; Masakazu Nishida; Hisashi Narahara
Journal:  Clin Med Pathol       Date:  2008-03-01

5.  Predictive diagnosis of endometrial hyperplasia and personalized therapeutic strategy in women of fertile age.

Authors:  Vadym M Goncharenko; Vasyl A Beniuk; Olga V Kalenska; Olga M Demchenko; Mykola Ya Spivak; Rostyslav V Bubnov
Journal:  EPMA J       Date:  2013-12-06       Impact factor: 6.543

6.  Effect of Hysteroscopic Polypectomy Combined with Mirena Placement on Postoperative Adverse Reactions and Recurrence Rate of Endometrial Polyps: Based on a Large-Sample, Single-Center, Retrospective Cohort Study.

Authors:  Yanli Shen; Wenguang Feng; Jing Yang; Jinling Yi
Journal:  Biomed Res Int       Date:  2022-04-26       Impact factor: 3.246

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.